Page 1

MedinCell MedinCell announces fiscal year consolidated results April 2020 - March 2021 Euronext : MEDCL⚫ Montpellier - France June 16 , 2021 - 5:45 pm CEST Income from ordinary activities : € 11.8 million ( + 96 % compared to the previous year ) Operating expenses : € 27.1 million ( + 8 % ) Cash consumption from operations : € 12.1 million Available cash : € 47.1 million + € 3.9 million of non - risky financial assets Estimated financial visibility until summer 2023 Key developments of the product portfolio over the period April 2020 - March 2021 • • • • Following the announcement of positive results for the Phase 3 trial of mdc - IRM / TV46000 ( schizophrenia ) in January 2021 , Teva Pharmaceuticals , which is leading and funding the program , is preparing for the U.S. regulatory filing , which is expected in mid - 2021 . Expected by the end of 2021 , the findings of the ongoing analysis of the results of the first - in - human study of mdc - TJK , the second program in partnership with Teva Pharmaceuticals , will drive future developments . End of the Phase 2 clinical trial of mdc - CWM ( post - operative pain and inflammation ) , developed with AIC . Our partner plans to launch new safety and efficacy clinical studies ( Phase 3 ) in 2021 . Selection of candidate formulations and entry into regulatory development of four new products : mdc - WWM ( contraception ) , mdc - GRT ( organ transplant ) , mdc - KPT ( pain / animal health ) and mdc - TTG ( prophylaxis against Covid - 19 and its variants ) . Post - closing : the company announced on June 15 , 2021 the selection of a candidate formulation for the mdc - STM ( malaria ) program supported by the international health agency Unitaid , paving the way for the launch of pre - clinical activities . Portfolio of products based on BEPO® technology in regulatory development as of June 16 , 2021 mdc - GRT Tacrolimus Organ Transplant mdc - TTG Ivermectin Covid - 19 mdc - WWM progestin molecule ( non - MPA ) Contraception mdc - ANG Confidential Antipsychotic mdc - STM Ivermectin Malaria mdc - KPT Confidential Pain mdc - TJK Confidential Antipsychotic mdc - CWM Celecoxib Pain & inflammation mdc - IRM Risperidone Schizophrenia Préclinic Clinical phase 1 Clinical phase 2 Clinical phase 3 In partnership with Teva Pharmaceuticals In partnership with AIC With the support of the Bill and Melinda Gates Foundation Internal programs * NDA : New Drug Application 1/7 NDA / Commercialization With the support of Unitaid Animal Health product ( different clinical development process )